Emergence of raltegravir-resistant HIV-1 in the central nervous system

被引：7
|
作者：
Watanabe, K. [1 ]
Honda, M. [1 ]
Watanabe, T. [1 ]
Tsukada, K. [1 ]
Teruya, K. [1 ]
Kikuchi, Y. [1 ]
Oka, S. [1 ]
Gatanaga, H. [1 ]
机构：
[1] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2010年 / 21卷 / 12期
关键词：
integrase; resistant; cerebrospinal fluid; Q148R; HIV; raltegravir; CEREBROSPINAL-FLUID; INFECTION;
D O I：
10.1258/ijsa.2009.009283
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Integrase inhibitor-resistant HIV-1 was detected in the cerebrospinal fluid, but not in the plasma of a 42-year-old man with HIV encephalopathy treated with a raltegravir (RAL)-containing regimen. Raltegravir resistance may develop in the central nervous system when the virus is already multi-drug resistant because of different penetration into cerebrospinal fluid of individual antiretroviral agents.
引用
收藏
页码：840 / 841
页数：2
相关论文
共 50 条
  • [1] Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
    Codoner, Francisco M.
    Pou, Christian
    Thielen, Alexander
    Garcia, Federico
    Delgado, Rafael
    Dalmau, David
    Ramon Santos, Jose
    Jose Buzon, Maria
    Martinez-Picado, Javier
    Alvarez-Tejado, Miguel
    Clotet, Bonaventura
    Ruiz, Lidia
    Paredes, Roger
    ANTIVIRAL RESEARCH, 2010, 88 (03) : 281 - 286
  • [2] Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: Design and characterization of the enzymatic properties
    Shadrina, Olga
    Krotova, Olga
    Agapkina, Julia
    Knyazhanskaya, Ekaterina
    Korolev, Sergey
    Starodubova, Elizaveta
    Viklund, Alecia
    Lukashov, Vladimir
    Magnani, Mauro
    Medstrand, Patrik
    Karpov, Vadim
    Gottikh, Marina
    Isaguliants, Maria
    BIOCHIMIE, 2014, 102 : 92 - 101
  • [3] Strategies to target HIV-1 in the central nervous system
    Gray, Lachlan R.
    Brew, Bruce J.
    Churchill, Melissa J.
    CURRENT OPINION IN HIV AND AIDS, 2016, 11 (04) : 371 - 375
  • [4] Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence
    Spudich, Serena
    Peterson, Julia
    Fuchs, Dietmar
    Price, Richard W.
    Gisslen, Magnus
    AIDS, 2019, 33 : S135 - S144
  • [5] Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties
    Stefic, Karl
    Chaillon, Antoine
    Bouvin-Pley, Melanie
    Moreau, Alain
    Braibant, Martine
    Bastides, Frederic
    Gras, Guillaume
    Bernard, Louis
    Barin, Francis
    PLOS ONE, 2017, 12 (08):
  • [6] HIV-1 and Alcohol: Interactions in the Central Nervous System
    Silverstein, Peter S.
    Kumar, Anil
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2014, 38 (03) : 604 - 610
  • [7] Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2
    Ocampo, Ferron F.
    Promsena, Pathariya
    Chan, Phillip
    CURRENT HIV/AIDS REPORTS, 2023, 20 (06) : 345 - 356
  • [8] Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system
    Cinque, P
    Bestetti, A
    Morelli, P
    Presi, S
    JOURNAL OF NEUROVIROLOGY, 2000, 6 : S95 - S102
  • [9] Apoptosis induced by HIV-1 infection of the central nervous system
    Shi, B
    DeGirolami, U
    He, JL
    Wang, S
    Lorenzo, A
    Busciglio, J
    Gabuzda, D
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (09) : 1979 - 1990
  • [10] Role of raltegravir in the management of HIV-1 infection
    Okeke, N. Lance
    Hicks, Charles
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2011, 3 : 81 - 92
12345